AbbVie (ABBV) announced that the FDA has granted its ABT-414, an investigational antibody drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR) Rare Pediatric Disease Designation for the treatment of pediatric patients with EGFR-amplified Diffuse Intrinsic Pontine Glioma, highly aggressive and difficult to treat brain tumors found at the base of the brain. The FDA granted the Rare Pediatric Disease Designation based on a proposed pediatric sub-study "nested" within the ongoing Phase 2 study of ABT-414 in adults with recurrent EGFR-amplified glioblastoma, conducted in collaboration with the European Organization for Research and Treatment of Cancer.